Navigation Links
Optovue Receives FDA Clearance on OCT Normative Database
Date:9/17/2010

FREMONT, Calif., Sept. 17 /PRNewswire/ -- Optovue, the company that launched the first FDA cleared fourier/spectral domain OCT in the U.S., announced that it has received 510(k) clearance on its Normative Database ("NDB") for the RTVue OCT device.

"This affirms that our protocols and management of this large international, multi-site normative population are at the level that FDA regulatory guidelines require," stated Mike Sinai, PhD, Sr. Director of Clinical Research for Optovue. "Most importantly, this demonstrates the safety and efficacy of our NDB based on FDA current standard for its intended uses. Furthermore, this is the only normative database taking into account patient age, signal strength of the scan, and even optic disk size in certain scans. These factors along with the large normal sampling, offers clinicians a high degree of confidence in our NDB as a reference tool in assessing retina nerve fiber thickness."

The NDB for the RTVue system comprises over 600 eyes for the pending U.S. release, and is the largest FDA cleared NDB for an OCT device. Optovue plans on releasing the RTVue application update containing the newly cleared NDB for customers in the next several weeks.

About RTVue and iVue

RTVue was the first FDA cleared Fourier domain (also known as spectral domain) OCT launched in the United States, and also the first OCT cleared by the U.S. Food and Drug Administration for both corneal and retinal imaging. The iVue is the compact fourier-domain version of the RTVue OCT, offering the same scanning speed and resolution as the larger system, that includes scanning and reports for retina, retina nerve fiber and cornea assessment by the clinician.

About Optovue (www.optovue.com)

Optovue Inc. is a privately-held ophthalmic device company dedicated to working with eye care professionals and clinical researchers to lead the commercialization of new imaging modalities that improve diagnosis and therapy of ocular disease. Optovue has achieved widespread market success through a combination of unique data analysis design, a reputation for excellent customer service, and rapid innovation of its technology in response to physician feedback. The company is headquartered in Fremont, CA, with operations in Carlsbad, CA and European operations in Heidelberg, Germany. Contact:Paul KealeyVice President Marketingpaul_kealey@optovue.com510-623-8868 ext. 105John TalaricoVice President Regulatoryjohn_talarico@optovue.com510-623-8868
'/>"/>

SOURCE Optovue Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Boston Scientific Receives Exclusive Expanded Indication for Its CRT-Ds
2. New England Biolabs Receives Award to Develop Novel Enzymatic Reagents for Epigenetic Studies
3. Amedica® Receives Patents for Innovative Motion-Preserving Total Disc Implant Featuring Silicon Nitride
4. Masimo Noninvasive and Continuous Hemoglobin Receives Market Clearance in Japan
5. Assured Pharmacy Receives $500,000 in Debt Financing
6. Arcion Therapeutics Receives FDA Fast Track Designation for ARC-4558 for the Treatment of Pain Associated with Painful Diabetic Neuropathy
7. QuantaLife, a New Life Science Tool Company, Receives NIH Grant
8. Roche Receives FDA Clearance for U.S. Launch of cobas 8000 Modular Analyzer Series for High-Volume Laboratory Testing
9. National University Hospital Singapore Receives DSRB Approval to Use TIGR® Matrix Surgical Mesh in a New Randomized Controlled TRAM Flap Study
10. CorMatrix Receives FDA IDE Approval to Begin Prospective, Randomized Evaluation of New Onset Postoperative Atrial Fibrillation in Subjects Receiving the CorMatrix® ECM™ for Pericardial Closure
11. Say Goodbye to Unwanted Love Handles: CoolSculpting by ZELTIQ™ Receives FDA Clearance for Patented, Non-Invasive Cooling Treatment for Fat Reduction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2017)... , Aug. 3, 2017  Agragen, LLC, a ... active in the biopharmaceutical, nutraceutical, and aquacultural feed ... of its lead drug candidates, AGR131.  This drug ... cytokine from the blood of patients suffering from ... inflammatory bowel disease. ...
(Date:8/2/2017)... and BENTON, Ky. , Aug. 2, 2017   Marshall County ... its environmental services (ES) team to proactively reduce the risk of hospital-acquired infections (HAIs). The ... disinfection robot that uses UVC light energy to kill deadly pathogens such as C. ... Tru-D SmartUVC ... Tru-D in action in ...
(Date:8/1/2017)... 1, 2017   CerSci Therapeutics , a non-opioid ... , has received notice from the National Institute ... Health (NIH) that it has been awarded a Direct-to-Phase ... $650,000 in 2017 with an additional $1,000,000 to follow ... Drug application of their lead non-opioid drug candidate CT-044 ...
Breaking Medicine Technology:
(Date:8/16/2017)... ... August 16, 2017 , ... Summer days spent with ... family-owned supermarket, has put together suggestions for enjoying the season of sunshine. Add trying ... everyone in the family can join in on the fun. , Try Something ...
(Date:8/16/2017)... ... August 16, 2017 , ... Blue Health Intelligence (BHI) announced today ... Officer. Dr. Spiro brings over 30 years of clinical, healthcare IT, value-based care, and ... analytics solutions. , “I am thrilled to welcome Dr. Spiro to BHI,” said ...
(Date:8/16/2017)... , ... August 16, 2017 , ... Greenfield Advisors is ... in the U.S. for the second year in a row. The Inc. 5000 list ... three years. , “To be on the list once is a great accomplishment, but ...
(Date:8/16/2017)... ... 2017 , ... The Data Council, the leading provider of ... by Advantage Solutions. The Data Council’s IX-ONE platform is the Specialty, Natural ... suppliers, brokers, distributors and retailers. The Data Council will become a part of ...
(Date:8/16/2017)... ... August 16, 2017 , ... For the second year, the ... to educate the public on the impact of concussions. Brooke Mills, student and ... Concussion Awareness Day. , Brooke is working diligently is to raise awareness of ...
Breaking Medicine News(10 mins):